Merck’s Simvastatin/Niacin Combination Delayed By Formulation Issues
This article was originally published in The Pink Sheet Daily
Executive Summary
Regulatory submission of the investigational HDL-raising, LDL-lowering fixed-dose combination, MK-0524B, had been planned for 2007.
You may also be interested in...
Merck’s Lipid-Lowering Combo Cordaptive Could Clear FDA In Mid-2008
The company announced it has filed the niacin and laropiprant combination, formerly known as MK-0524A.
Merck’s Lipid-Lowering Combo Cordaptive Could Clear FDA In Mid-2008
The company announced it has filed the niacin and laropiprant combination, formerly known as MK-0524A.
Merck R&D Renaissance To Continue With Three NDA Filings In 2007
During Dec. 12 investor meeting, Merck Research Labs President Peter Kim says firm will file NDAs for compounds to treat HIV, insomnia and atherosclerosis in 2007.